UPDATE: Ascendiant Capital Markets Downgrades Repros Therapeutics Following Announcement of FDA Concerns
October 24, 2013 at 10:17 AM EDT
In a report published Thursday, Ascendiant Capital Markets analyst Keay Nakae downgraded the rating on Repros Therapeutics (NASDAQ: RPRX ) from Strong Buy to Buy, but reiterated the $25.00 price target. In the report, Ascendiant Capital Markets noted, “Yesterday, the company announced that the FDA communicated to them that it
